November 2017: Lung cancer diagnosis

February 2018: 2-week biospecimen collected

June 2018: 3-month biospecimen collected

January 2019: 9-month biospecimen collected

May 2019: 12-month (posttoxicity) biospecimen collected

November 2019: Ophthalmology follow-up notes improvement in visual fields January 2018: Pembrolizumab started; baseline biospecimen collected

March 2018: 6-week biospecimen collected

October 2018: 6-month biospecimen collected

April 2019: Clinical presentation with visual changes

MRI: No nerve entrapment or enhancement of orbits or optic nerves

Labs: CRP 88

Pathology: Negative for active or healed arteritis

Treatment: Pembrolizumab stopped; methylprednisone 1g IV daily for 3 days, followed by prednisone taper starting at 60 mg PO daily

August 2021: Ophthalmology follow-up. Patient reports vision is stable.